Valneva says UK revokes IXCHIQ vaccine authorization

Valneva said the UK MHRA revoked the marketing authorization for IXCHIQ after a further benefit-risk assessment by the CHM. The company said it expects no recall expense and only minimal impact on sales because it had not actively distributed the vaccine in the UK for months.